Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Startup Spotlight
Deep Dives
Archive
About
Latest
Top
Discussions
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69
Job cuts to refocus Wegovy/Ozempic; pacibekitug joins Novartis; Revolution Medicines shows early first-line activity; BioNTech/DualityBio scores an ADC…
Sep 12
•
Katerina Roznik
1
Ionis' Olezarsen Win, Novartis Licenses Arrowhead, CDC Vaccine Fight — This Week in Biotech #68
Ionis olezarsen’s Phase 3 in sHTG cuts triglycerides & pancreatitis. RFK Jr. reshapes ACIP again. Florida vaccine mandate rollback. United Therapeutics…
Sep 5
•
Katerina Roznik
2
August 2025
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
Public health politics escalate as COVID rules shift, Novo backs Replicate’s next-gen RNA, and ImmunityBio posts 100% disease control in glioblastoma…
Aug 29
•
Katerina Roznik
4
Viking Falls on Obesity Pill, Rocket’s Gene Therapy Resumes, FDA Greenlights Papzimeos — This Week in Biotech #66
Precigen soars on RRP approval, Rocket rebounds after clinical hold, Viking disappoints on tolerability, and Gilead makes a $350M CAR-T bet with…
Aug 22
•
Katerina Roznik
4
Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through — This Week in Biotech #65
Plus: The latest on Sarepta’s financial strategy, Insmed’s lung disease win, and Schrödinger’s early-stage setback (August 8–14, 2025).
Aug 15
•
Katerina Roznik
and
Erin Mihealsick
3
1
RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64
Biotech Q2 round-up: Sarepta rebounds, Eli Lilly’s oral GLP-1 disappoints, and U.S. vaccine strategy pivots away from mRNA (August 1–7, 2025).
Aug 8
•
Katerina Roznik
4
FDA Shake Up, Sarepta Rebounds, and Trump Targets Drug Prices — This Week in Biotech #63
Prasad’s resignation boosts biotech stocks, Sarepta regains ground, and Trump demands global price matching from pharma CEOs (July 25–31, 2025).
Aug 1
•
Katerina Roznik
and
Erin Mihealsick
3
July 2025
Sarepta, Elevidys, and the Future of AAV Gene Therapy
Part 2 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
Jul 29
•
Katerina Roznik
and
The Biotech Capital Compass
6
Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech #62
FDA setbacks, insider buys, trial wins, and pipeline pivots (July 18–24, 2025).
Jul 25
•
Katerina Roznik
and
Erin Mihealsick
4
Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in Biotech #61
Layoffs, CRLs, and standout trial data from Sarepta, MiNK, SELLAS, DiaMedica, and more (July 11–17, 2025).
Jul 18
•
Katerina Roznik
and
Erin Mihealsick
3
1
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
Part 1 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
Jul 17
•
Katerina Roznik
4
KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — This Week in Biotech #60
FDA nods, big M&A, and major trial wins (July 3–10, 2025).
Jul 11
•
Katerina Roznik
and
Erin Mihealsick
3
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
